Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use VABRINTY™ safely and effectively. See full prescribing information for VABRINTY. VABRINTY (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002
Medication labelWhy this: Advisory · dailymed-prescription
VABRINTY is indicated for the treatment of advanced prostate cancer.
- generic_name
- leuprolide acetate
- product_names
- Leuprolide acetate
- ndc
- 85043-025, 85043-025-02, 85043-045, 85043-045-04, 85043-030, 85043-030-03, 85043-075, 85043-075-05, 85043-075-50
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en